New ways to make hard-to-treat breast cancer cells more responsive to chemotherapy
Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer
This study is looking at ways to help patients with triple negative breast cancer who still have some cancer cells left after treatment, by finding a way to wake up those stubborn cells so they can be treated more effectively with chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11105852 on NIH RePORTER |
What this research studies
This research focuses on patients with triple negative breast cancer (TNBC) who have persistent minimal residual disease despite initial treatment. It aims to identify a specific signaling pathway that keeps rare, low-proliferative tumor cells dormant and resistant to therapy. By inhibiting this pathway, the researchers hope to reactivate these cells, making them more susceptible to chemotherapy. The study will involve clinical trials to test this new approach in patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have minimal residual disease after neoadjuvant therapy.
Not a fit: Patients with non-triple negative breast cancer or those without minimal residual disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with triple negative breast cancer by effectively targeting and eliminating resistant tumor cells.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Tran, David D — University of Southern California
- Study coordinator: Tran, David D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.